NeuroSolutions has established expertise in delivering first class preclinical translational research

NeuroSolutions is a contract research organisation established in 2001 as a service provider of cutting edge electrophysiological and behavioural research in the field of neuroscience.

Publications
Posters

Pain

NeuroSolutions has established expertise in delivering first class preclinical translational research into pain, particularly around the development of new treatments into neuropathic and inflammatory pain. We have worked extensively in rodent tissue and have recently expanded our capabilities to record from non-human primate and post-mortem human tissue

Disease Areas Behavioural Tests Electrophysiological Assays
Disease Areas
  • Chronic constriction injury
  • Spinal nerve ligation
  • Diabetes-induced
  • Chemotherapy-induced
  • Fracture pain model
  • Carrageenan
  • Complete Freund’s adjuvant
  • Formalin
  • MIA
  • UVB
  • Surgical pain
Behavioural Tests
  • Von Frey hair
  • Hargreave’s
  • Randall-Selitto
  • Weight-bearing
  • Paw licking, shaking, lifting
  • Plethysmography
  • RotaRod test
Behavioural Tests

In vivo: Single fibre recording, spontaneous and evoked, single neurone recording from the spinal cord and brain, all naïve and modelled animals

In vitro: Compound action potential recording from isolated nerves, naïve and modelled, slice patch-clamp recordings, dissociated DRG patch-clamp recordings from naïve and modelled animals

 

"Thank you for the absolutely phenomenal work you have done for Redpin. As biotech managers, we frequently push CROs to the max and sometimes take them for granted. After reviewing the work that you have done over the past year, I felt that I needed to let you know what a difference you had made to Redpin’s growth and success. Your work has been of the highest caliber and your dedication unmatched."

Elma Hawkins PhD, MBA, former President and CEO Redpin Therapeutics, Inc.

"I have worked with NeuroSolutions on many projects over many years. The quality of the data is second to none, their scientific expertise and collaborative approach to our technicality demanding projects has been excellent. For example, the work on SEN1576 has led to high-impact joint publications with Senexis and this compound is now being developed by Talisman Therapeutics.."

Dr Mark Treherne - As former Chief Executive of Senexis Limited (Dr Treherne is currently Chief Executive of Life Sciences Organisation at UK Trade & Investment, which helps UK business trade overseas).

In partnership with
Science Exchange
Pacific Discovery Services
scientist.com
NeuroSolutions Ltd

Email: info@nsolns.com
Contact Head-office on +44 (0) 8454 500171


One of our partner companies may be better suited to your requirements

AUSTRALASIA
Pacific Discovery Services

Email: info@pacificdiscoveryservices.com